158 related articles for article (PubMed ID: 37400682)
1. Adverse Outcomes, Healthcare Resource Utilization, and Costs Associated with Systemic Corticosteroid use Among Adults with Systemic Lupus Erythematosus in the UK.
Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
Rheumatol Ther; 2023 Oct; 10(5):1167-1182. PubMed ID: 37400682
[TBL] [Abstract][Full Text] [Related]
2. Healthcare Resource Use and Costs Associated with Organ Damage in Newly Diagnosed Adults with Systemic Lupus Erythematosus in the UK.
Stirnadel-Farrant HA; Golam SM; Naisbett-Groet B; Gibson D; Langham J; Langham S; Samnaliev M
Rheumatol Ther; 2023 Oct; 10(5):1183-1197. PubMed ID: 37400683
[TBL] [Abstract][Full Text] [Related]
3. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma.
Voorham J; Xu X; Price DB; Golam S; Davis J; Zhi Jie Ling J; Kerkhof M; Ow M; Tran TN
Allergy; 2019 Feb; 74(2):273-283. PubMed ID: 29987879
[TBL] [Abstract][Full Text] [Related]
4. Healthcare resource utilization and costs associated with long-term corticosteroid exposure in patients with systemic lupus erythematosus.
Kabadi S; Yeaw J; Bacani AK; Tafesse E; Bos K; Karkare S; DeKoven M; Vina ER
Lupus; 2018 Oct; 27(11):1799-1809. PubMed ID: 30068254
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Costs and Utilization for Patients With Systemic Lupus Erythematosus in China: A National Claims Database Study.
He X; Lloyd E; Cooper S; Li L; Chauhan D; Juliao P; Quasny H; Bao C
Value Health Reg Issues; 2023 Sep; 37():88-96. PubMed ID: 37379801
[TBL] [Abstract][Full Text] [Related]
6. Clinical and Economic Burden of Systemic Lupus Erythematosus in the Years Preceding End-Stage Kidney Disease Diagnosis: A Retrospective Observational Study.
Huang SP; Guisinger A; Averell C; Bell CF; Rubin B
Rheumatol Ther; 2023 Jun; 10(3):551-562. PubMed ID: 36738424
[TBL] [Abstract][Full Text] [Related]
7. An evaluation of costs associated with overall organ damage in patients with systemic lupus erythematosus in the United States.
Bell CF; Ajmera MR; Meyers J
Lupus; 2022 Feb; 31(2):202-211. PubMed ID: 35060407
[TBL] [Abstract][Full Text] [Related]
8. Prolonged oral corticosteroid treatment in patients with systemic lupus erythematosus: An evaluation of 12-month economic and clinical burden.
Huang SP; DerSarkissian M; Gu YM; Duh MS; Wang MJ; Benson J; Vu J; Averell C; Bell CF
J Manag Care Spec Pharm; 2023 Apr; 29(4):365-377. PubMed ID: 36989451
[No Abstract] [Full Text] [Related]
9. Healthcare Resource Utilization and Associated Costs in Patients With Systemic Lupus Erythematosus Diagnosed With Lupus Nephritis.
Bell CF; Wu B; Huang SP; Rubin B; Averell CM; Chastek B; Hulbert EM; Von Feldt J
Cureus; 2023 Apr; 15(4):e37839. PubMed ID: 37214060
[TBL] [Abstract][Full Text] [Related]
10. Systemic Corticosteroid-related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal Polyposis.
Davis GE; Zeiger RS; Emmanuel B; Chung Y; Tran TN; Evans KA; Chen S; Katial R; Kreindler JL; Tkacz J
Clin Ther; 2022 Sep; 44(9):1187-1202. PubMed ID: 36057475
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
Lokhandwala T; Coutinho AD; Bell CF
Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
[TBL] [Abstract][Full Text] [Related]
12. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
Loncharich MF; Anderson CW
ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
[TBL] [Abstract][Full Text] [Related]
13. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
Value Health Reg Issues; 2024 Jun; 43():101001. PubMed ID: 38850589
[TBL] [Abstract][Full Text] [Related]
14. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study.
Cortés-Hernández J; Marras Fernández-Cid C; Andreu Sánchez JL; Calvo Alén J; García-Aparicio AM; Díez Álvarez E; Hidalgo Bermejo FJ; Coronell C; Perna A; Ordi Ros J
Reumatol Clin (Engl Ed); 2023; 19(6):312-318. PubMed ID: 37286267
[TBL] [Abstract][Full Text] [Related]
15. Burden of illness and costs associated with eosinophilic granulomatosis with polyangiitis: evidence from a managed care database in the United States.
Bell CF; Blauer-Peterson C; Mao J
J Manag Care Spec Pharm; 2021 Sep; 27(9):1249-1259. PubMed ID: 34165321
[No Abstract] [Full Text] [Related]
16. Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004-2015.
Jiang M; Near AM; Desta B; Wang X; Hammond ER
Lupus Sci Med; 2021 Sep; 8(1):. PubMed ID: 34521733
[TBL] [Abstract][Full Text] [Related]
17. Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel.
Petri M; Bechtel B; Dennis G; Shah M; McLaughlin T; Kan H; Molta C
Lupus; 2014 Sep; 23(10):1006-13. PubMed ID: 24786783
[TBL] [Abstract][Full Text] [Related]
18. Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease.
King A; Rajpura J; Liang Y; Paprocki Y; Uzoigwe C
Curr Med Res Opin; 2022 Nov; 38(11):1831-1840. PubMed ID: 36134459
[TBL] [Abstract][Full Text] [Related]
19. Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.
Oglesby A; Korves C; Laliberté F; Dennis G; Rao S; Suthoff ED; Wei R; Duh MS
Appl Health Econ Health Policy; 2014 Apr; 12(2):179-90. PubMed ID: 24573911
[TBL] [Abstract][Full Text] [Related]
20. The cost of flares among patients with systemic lupus erythematosus with and without lupus nephritis in the United States.
Bell CF; Huang SP; Cyhaniuk A; Averell CM
Lupus; 2023 Feb; 32(2):301-309. PubMed ID: 36542670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
